Aldo A Bernasconi1, Michelle M Wiest2, Carl J Lavie3, Richard V Milani3, Jari A Laukkanen4. 1. Global Organization for EPA and DHA Omega-3s (GOED), Salt Lake City, UT. Electronic address: aldo@goedomega3.com. 2. Department of Statistical Science, University of Idaho, Moscow, ID. 3. Department of Cardiovascular Diseases, John Ochsner Heart and Vascular Institute, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, LA. 4. Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland Department of Medicine, Central Finland Health Care District, Jyväskylä, Finland.
Abstract
OBJECTIVES: To quantify the effect of eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids on cardiovascular disease (CVD) prevention and the effect of dosage. METHODS: This study is designed as a random effects meta-analysis and meta-regression of randomized control trials with EPA/DHA supplementation. This is an update and expanded analysis of a previously published meta-analysis which covers all randomized control trials with EPA/DHA interventions and cardiovascular outcomes published before August 2019. The outcomes included are myocardial infarction (MI), coronary heart disease (CHD) events, CVD events (a composite of MI, angina, stroke, heart failure, peripheral arterial disease, sudden death, and non-scheduled cardiovascular surgical interventions), CHD mortality and fatal MI. The strength of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation framework. RESULTS: A total of 40 studies with a combined 135,267 participants were included. Supplementation was associated with reduced risk of MI (relative risk [RR], 0.87; 95% CI, 0.80 to 0.96), high certainty number needed to treat (NNT) of 272; CHD events (RR, 0.90; 95% CI, 0.84 to 0.97), high certainty NNT of 192; fatal MI (RR, 0.65; 95% CI, 0.46 to 0.91]), moderate certainty NNT = 128; and CHD mortality (RR, 0.91; 95% CI, 0.85 to 0.98), low certainty NNT = 431, but not CVD events (RR, 0.95; 95% CI, 0.90 to 1.00). The effect is dose dependent for CVD events and MI. CONCLUSION: Cardiovascular disease remains the leading cause of death worldwide. Supplementation with EPA and DHA is an effective lifestyle strategy for CVD prevention, and the protective effect probably increases with dosage.
OBJECTIVES: To quantify the effect of eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids on cardiovascular disease (CVD) prevention and the effect of dosage. METHODS: This study is designed as a random effects meta-analysis and meta-regression of randomized control trials with EPA/DHA supplementation. This is an update and expanded analysis of a previously published meta-analysis which covers all randomized control trials with EPA/DHA interventions and cardiovascular outcomes published before August 2019. The outcomes included are myocardial infarction (MI), coronary heart disease (CHD) events, CVD events (a composite of MI, angina, stroke, heart failure, peripheral arterial disease, sudden death, and non-scheduled cardiovascular surgical interventions), CHD mortality and fatal MI. The strength of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation framework. RESULTS: A total of 40 studies with a combined 135,267 participants were included. Supplementation was associated with reduced risk of MI (relative risk [RR], 0.87; 95% CI, 0.80 to 0.96), high certainty number needed to treat (NNT) of 272; CHD events (RR, 0.90; 95% CI, 0.84 to 0.97), high certainty NNT of 192; fatal MI (RR, 0.65; 95% CI, 0.46 to 0.91]), moderate certainty NNT = 128; and CHD mortality (RR, 0.91; 95% CI, 0.85 to 0.98), low certainty NNT = 431, but not CVD events (RR, 0.95; 95% CI, 0.90 to 1.00). The effect is dose dependent for CVD events and MI. CONCLUSION:Cardiovascular disease remains the leading cause of death worldwide. Supplementation with EPA and DHA is an effective lifestyle strategy for CVD prevention, and the protective effect probably increases with dosage.
Authors: Jeffery L Heileson; Jared M McGowen; Jose M Moris; Tomas J Chapman-Lopez; Ricardo Torres; LesLee K Funderburk; Jeffrey S Forsse Journal: J Int Soc Sports Nutr Date: 2022-07-05 Impact factor: 4.948
Authors: Harold E Bays; Anandita Kulkarni; Charles German; Priyanka Satish; Adedapo Iluyomade; Ramzi Dudum; Aarti Thakkar; Mahmoud Al Rifai; Anurag Mehta; Aneesha Thobani; Yousif Al-Saiegh; Adam J Nelson; Samip Sheth; Peter P Toth Journal: Am J Prev Cardiol Date: 2022-04-06
Authors: Robert C Block; Gregory C Shearer; Ashley Holub; Xin M Tu; Shaker Mousa; J Thomas Brenna; William S Harris; Nathan Tintle Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2021-04-24 Impact factor: 3.015
Authors: Andrew Elagizi; Carl J Lavie; Evan O'Keefe; Keri Marshall; James H O'Keefe; Richard V Milani Journal: Nutrients Date: 2021-01-12 Impact factor: 5.717
Authors: Michael I McBurney; Jeffrey B Blumberg; Rebecca B Costello; Manfred Eggersdorfer; John W Erdman; William S Harris; Elizabeth J Johnson; Susan Hazels Mitmesser; Robert C Post; Deshanie Rai; Leon J Schurgers Journal: Nutrients Date: 2021-05-28 Impact factor: 5.717
Authors: Harold E Bays; Pam R Taub; Elizabeth Epstein; Erin D Michos; Richard A Ferraro; Alison L Bailey; Heval M Kelli; Keith C Ferdinand; Melvin R Echols; Howard Weintraub; John Bostrom; Heather M Johnson; Kara K Hoppe; Michael D Shapiro; Charles A German; Salim S Virani; Aliza Hussain; Christie M Ballantyne; Ali M Agha; Peter P Toth Journal: Am J Prev Cardiol Date: 2021-01-23